A Drug with Two Prices
After 20 years, the monopoly for Abbvie’s Humira (adalimumab) has ended with the recent entry of Amgen’s biosimilar Amjevita. However, Amgen’s dual pricing strategy for its product has been raising some eyebrows.
After 20 years, the monopoly for Abbvie’s Humira (adalimumab) has ended with the recent entry of Amgen’s biosimilar Amjevita. However, Amgen’s dual pricing strategy for its product has been raising some eyebrows.
‘The Price of Business’: Discussing the Future of Working at Home
On April 13, Alex Brill joined Kevin Price on ‘The Price of Business’ discussing the future of working from home.
Listen here. Other interviews with Kevin Price can be found here, here and here.
Last week, the Senate Committee on Health, Education, Labor and Pensions held a hearing titled “Examining Health Care Workforce Shortages: Where Do We Go From Here?”
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.